Patient agreement to systemic anti-cancer therapy (SACT):

Venetoclax - Obinutuzumab

Hospital/NHS Trust/NHS Board: _____

_____

_____

Responsible consultant:

Name: _____

Job title: _____

Patient details

Patient's surname/family name: _____

_____

Patient's first name(s): _____

_____

Date of birth: _____

NHS number: _____
(or other identifier)

Special requirements:
(e.g. other language/other communication method)

_____

_____

_____

_____

_____

_____

Name of proposed course of treatment (include brief explanation if medical term not clear)

☐ Venetoclax and Obinutuzumab for the treatment of chronic lymphocytic leukaemia (CLL).

☐ Obinutuzumab is given intravenously. On cycle 1, Obinutuzumab is given on days 1, 2, 8 and 15. On cycles 2 - 6, Obinutuzumab is given on day 1 only.

☐ Venetoclax is taken orally once a day. It will be started after you have begun Obinutuzumab.

☐ Each treatment cycle lasts for 28 days. Treatment with Obinutuzumab Is continued for up to 6 cycles. Treatment with Venetoclax is continued for up to 1 year (12 cycles).

☐ When Venetoclax is started, your dose will increase gradually (a dose-titration schedule) until it reaches the optimal maintenance dose. Your blood tests will be monitored to ensure that this is the optimal dose of Venetoclax for you, with acceptable side-effects.

Where the treatment will be given

☐ Outpatient ☐ Day unit/case ☐ Inpatient ☐ Other: _____

Statement of health professional

(to be filled in by health professional with appropriate knowledge of proposed procedure, as specified in the hospital/Trust/NHS board's consent policy)

☑ Tick all relevant boxes

☐ I confirm the patient has capacity to give consent.

☐ **I have explained the course of treatment and intended benefit to the patient.**

The intended benefits (there are no guarantees about outcome)

☐ **Disease control** – the aim is not to cure but to control the disease and reduce the symptoms

☐ **To obtain or maintain remission of your leukaemia, in order to improve both quality and quantity of life.**

Statement of health professional

(continued)

Patient identifier/label

Significant, unavoidable or frequently occurring risks

Common side effects:

More than 10 in every 100 (>10%) people have one or more of the side effects listed:

- ☐ An increased risk of getting an infection from a drop in white blood cells – it is harder to fight infections and you can become very ill.
- ☐ **If you have a severe infection this can be life threatening. Contact your doctor or hospital straight away if:**
  - **your temperature goes over 37.5°C or over 38°C, depending on the advice given by your chemotherapy team**
  - **you suddenly feel unwell (even with a normal temperature)**
- ☐ Tiredness and feeling weak (fatigue).
- ☐ Diarrhoea, constipation, feeling sick (nausea), being sick (vomiting), tummy (abdominal) discomfort.
- ☐ Anaemia (due to low red blood cells).
- ☐ Changes in kidney function (which is monitored).
- ☐ Higher levels of electrolytes (potassium, calcium, phosphate), picked up in blood tests.
- ☐ Reactions can happen while Obinutuzumab is being given or within a few days. They are usually most noticeable with the first infusions: flu-like symptoms, high or low blood pressure, flushing, shortness of breath, feeling or being sick, faster or irregular heartbeat, allergic reactions (severe reactions are less common).
- ☐ Obinutuzumab may cause: indigestion, bruising and bleeding, pain in the hands, feet, joints and back, difficulty sleeping, thinning of the hair or hair loss, dry and itchy skin, headache, cough, high blood pressure.

Occasional side effects:

Between 1 and 10 in every 100 (1-10%) people have one or more of these effects:

- ☐ Increased risk of tumour lysis syndrome (when treatment destroys cancer cells too quickly for the kidneys to cope). Rarely, dialysis is needed. You will be prescribed medicines for prevention.
- ☐ Obinutuzumab may cause: an increased risk of a second cancer (years later), feeling sad and anxious, increased weight, an abnormal opening in the digestive tract (causing intense tummy pain, blood in the vomit or stools), changes in heart rhythm, difficulty and pain passing urine.

Other risks:

- ☐ All intravenous drugs may leak out of the vein while it is being given (extravasation) and can damage the tissue around the vein. It is not common, but important to deal with quickly. Tell the nurse straight away if you have any stinging, pain, redness or swelling around the vein.
- ☐ Side-effects with the anti-sickness medication may include: constipation, headaches, indigestion, difficulty sleeping and agitation.
- ☐ Before treatment, you might have blood tests to check for viruses (Hepatitis B, Hepatitis C, HIV or more unusual infections). This treatment may weaken your natural defence (immune) system making you prone to infections. Existing infections could worsen or become active again if you've had them in the past. You may be given medicines to prevent or treat infection.
- ☐ Severe skin reactions (called Steven Johnson Syndrome or Toxic Epidermal Necrolysis) causing tender red patches which blister and peel.
- ☐ Changes in memory, concentration or ability to think clearly. There can be many causes including your treatment, diagnosis, or both.
- ☐ Some anti-cancer medicines can damage ovaries and sperm. This may lead to infertility and/or early menopause.
- ☐ Some anti-cancer medicines may damage the development of a baby in the womb. It is important not to become pregnant or make someone else pregnant during treatment and for 18 months following Obinutuzumab and 30 days following Venetoclax. Use effective contraception during this time. Venetoclax may affect how well hormonal contraceptives work. Talk to your doctor or nurse.
- ☐ Complications of treatment can very occasionally be life threatening and may result in death. The risks are different for every individual. Potentially life threatening complications include those listed on this form, but, other, exceedingly rare side-effects may also be life threatening.

Statement of health professional

(continued)

Patient identifier/label

Any other risks and information

_____

_____

_____

☐ I have discussed the intended benefit and risks of the recommended treatment, and of any available alternative treatments (including no treatment).

☐ I have discussed the side effects of the recommended treatment, which could affect the patient straight away or in the future, and that there may be some side effects not listed because they are rare or have not yet been reported. Each patient may experience side effects differently.

☐ I have discussed what the treatment is likely to involve (including inpatient / outpatient treatment, timing of the treatment, blood and any additional tests, follow-up appointments etc) and location.

☐ I have explained to the patient, that they have the right to stop this treatment at any time and should contact the responsible consultant or team if they wish to do so.

☐ I have discussed concerns of particular importance to the patient in regard to treatment

(please write details here): _____

_____

_____

Clinical management guideline/Protocol compliant (please tick):

☐ Yes ☐ No ☐ Not available

If No please document reason here: _____

_____

The following written information has been provided:

☐ Information leaflet for Venetoclax and Obinutuzumab and/or individual drugs

☐ 24 hour alert card or SACT advice service contact details

☐ SACT treatment record (cruk.org/treatment-record)

☐ Other, please state: _____

Health professional details:

Signed: _____

Date: _____

Name (PRINT): _____

_____

Job title: _____

_____

Statement of interpreter (where appropriate)

Interpreter booking reference (if applicable): _____

I have interpreted the information above to the patient to the best of my ability and in a way in which I believe they can understand.

Signed: _____ Date: _____

Name (PRINT): _____

Job title: _____

Statement of patient

Patient identifier/label

Please read this form carefully. If your treatment has been planned in advance, you should already have your own copy of the form which describes the benefits and risks of the proposed treatment. If not, you will be offered a copy now. If you have any further questions, do ask – we are here to help you. You have the right to change your mind at any time, including after you have signed this form.

☐ I have **had enough time to consider** my options and make a decision about treatment.

☐ **I agree** to the course of treatment described on this form.

A witness should sign below if the patient is unable to sign but has indicated their consent. A person with parental responsibility will be asked to sign for young people under the age of 16 years.

Patient's signature: _____

Name (PRINT): _____ Date: _____

Person with parental responsibility/witness' signature: _____

Name (PRINT): _____ Date: _____

Copy accepted by patient: yes / no (please circle)

Confirmation of consent

(health professional to complete when the patient attends for treatment, if the patient has signed the form in advance)

On behalf of the team treating the patient, I have confirmed that the patient has no further questions and wishes the course of treatment/procedures to go ahead.

Signed: _____

Date: _____

Name (PRINT): _____

Job title: _____

Important notes: (tick if applicable)

☐ See also advance decision to refuse treatment

☐ Patient has withdrawn consent (ask patient to sign /date here)

Signed:_____

Date: _____

Further information for patients

Contact details (if patient wishes to discuss options later):

_____

Contact your hospital team if you have any questions about cancer and its treatment.

Cancer Research UK can also help answer your questions about cancer and treatment. If you want to talk in confidence, call our information nurses on freephone **0808 800 4040**, Monday to Friday, 9am to 5pm. Alternatively visit **www.cruk.org** for more information.

These forms have been produced by Guy's and St. Thomas' NHS Foundation Trust as part of a national project to support clinicians in ensuring all patients are fully informed when consenting to SACT. The project is supported by Cancer Research UK. This does not mean you are taking part in a clinical trial.

CANCER RESEARCH UK

Guidance for health professionals (to be read in conjunction with the hospital's consent policy)

Patient identifier/label

What a consent form is for

This form documents the patient's agreement to go ahead with the treatment you have proposed. It is not a legal waiver – if patients, for example, do not receive enough information on which to base their decision, then the consent may not be valid, even though the form has been signed. Patients are also entitled to change their mind after signing the form, if they retain capacity to do so. The form should act as an aide-memoir to health professionals and patients, by providing a checklist of the kind of information patients should be offered, and by enabling the patient to have a written record of the main points discussed. In no way should the written information provided for the patient be regarded as a substitute for face-to-face discussions with the patient.

The law on consent

See the following publications for a comprehensive summary of the law on consent. Consent: Patients and doctors making decisions together, GMC 2020 (www.gmc-uk.org/guidance). Reference guide to consent for examination or treatment, Department of Health, 2nd edition 2009 (www.doh.gov.uk).

Who can give consent

Everyone aged 16 or over is presumed to have the capacity to give consent for themselves, unless the opposite is demonstrated. For young people, it is good practice to involve those with parental responsibility in the consent discussions, unless specifically asked not to. A person with parental responsibility must sign this form for a child or young person under the age of 16. Such patients should be given the opportunity to 'assent' to treatment if they wish. If a patient has the capacity to give consent but is physically unable to sign a form, you should complete this form as usual and ask an independent witness to confirm that the patient has given consent orally or non-verbally.

When NOT to use this form

If the patient lacks the capacity to give consent, you should use an alternative form available for this purpose (dependent on patient age). A patient lacks capacity if they have an impairment or disturbance of the brain, affecting the way their mind works. For example, if they cannot do one of the following:

- understand information about the decision to be made
- retain that information in their mind
- use or weigh this information as a part of their decision making process, or
- communicate their decision (by talking, using sign language or any other means)

You should always take all reasonable steps (for example involving more specialist colleagues) to support a patient in making their own decision, before concluding that they are unable to do so.

Relatives cannot be asked to sign a form on behalf of an adult who lacks capacity to consent for themselves, unless they have been given the authority to do so under a Lasting Power of Attorney or as a court deputy.

Information

Information about what the treatment will involve, its benefits and risks (including side-effects and complications) and the alternatives to the particular procedure proposed, is crucial for patients when making up their minds. The courts have stated that patients should be told about 'significant risks which would affect the judgement of a reasonable patient'. 'Significant' has not been legally defined, but the GMC requires doctors to tell patients about 'significant, unavoidable or frequently occurring' risks. In addition if patients make clear they have particular concerns about certain kinds of risk, you should make sure they are informed about these risks, even if they are very small or rare. You should always answer questions honestly. Sometimes, patients may make it clear that they do not want to have any information about the options, but want you to decide on their behalf. In such circumstances, you should do your best to ensure that the patient receives at least very basic information about what is proposed. Where information is refused, you should document this on the consent form or in the patient's notes.

NHS Scotland

NHS Scotland staff should refer to Healthcare Improvement Scotland. Guidance on consent for SACT and local NHS Board guidance on consent aligned to the Scottish legal framework.

References

1. Summary of Product Characteristics (SmPCs) for individual drugs: https://www.medicines.org.uk/emc
2. Cancer Research UK: https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs
3. Macmillan Cancer Support: https://www.macmillan.org.uk/information-and-support/treating/chemotherapy/drugs-and-combination-regimens
4. Guy's and St. Thomas' NHS Foundation Trust, Chemotherapy consent